Phaseline

Companies › Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics

Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 4 registered trials: 2 Phase 3, 2 Phase 2; Metabolic and endocrine; next expected readout Sep 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
aleniglipron
GLP-1 receptor agonist
GLP1RPhase 3Obesity; Obesity, Overweight, or Chronic Weight Management; ObeseSep 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07169942aleniglipronPhase 2Obesity, Overweight, or Chronic Weight ManagementMetabolic and endocrineSep 2026
NCT07400588aleniglipronPhase 2ObeseMetabolic and endocrineSep 2026
NCT07654374aleniglipronPhase 3ObesityMetabolic and endocrineSep 2028
NCT07654361aleniglipronPhase 3ObesityMetabolic and endocrineSep 2028

Targets

GLP1R (1)

Companies with the same targets

Eli Lilly Novo Nordisk Roche Hangzhou Sciwind Biosciences Hangzhou Zhongmei Huadong Pharmaceutical Hanmi Pharmaceutical Company AstraZeneca Amgen Regeneron Pharmaceuticals Green Valley (Shanghai) Pharmaceuticals

Companies built like this

Chendu DIAO Pharmaceutical Group Beijing QL Biopharmaceutical Beijing Dongfang Biotech Kailera BrightGene New Bio-Medical Technology(Wuxi) Co.Ltd.

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.